The first FDA-approved thrombolytic for stroke, the recombinant human tissue plasminogen activator (tPA), was approved in 1995 given its 28% reduction in 90-day disability as measured by the modified Rankin Scale (mRS) [3]. Here, PLAT is linked to Stroke.